ArQule, Inc. (ARQL) Release: Data Presented at European Cancer Congress Suggest Clinical Benefit of Tivantinib in Patients With MET High Non-Squamous Non-Small Cell Lung Cancer  
9/30/2013 9:53:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WOBURN, Mass.--(BUSINESS WIRE)--Data presented at the European Cancer Congress demonstrated clinical benefits of treatment with the combination of tivantinib and erlotinib in patients with non-squamous, non-small cell lung cancer (NSCLC) whose tumors expressed high levels of MET protein (Abstract number 3410, MARQUEE: a randomized, double-blind, placebo-controlled, phase 3 trial of tivantinib [ARQ 197] plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer).

Help employers find you! Check out all the jobs and post your resume.